Table 1 Baseline characteristics of patients recruited in this study

Gender, n(%)

0.363

 Female

1163(36.4)

98(40.0)

28(41.8)

1289(36.7)

 Male

2033(63.6)

147(60.0)

39(58.2)

2219(63.3)

Age, n(%)

0.031

 ≥ 50

2643(82.7)

217(88.6)

52(77.6)

2912(83.0)

 < 50

553(17.3)

28(11.4)

15(22.4)

596(17.0)

BMI, n(%)

0.410

 ≤ 24

2182(68.4)

162(66.1)

50(74.6)

2394(68.3)

 > 24

1009(31.6)

83(33.9)

17(25.4)

1109(31.7)

CEA, n(%)

< 0.001

 ≤ 5

2084(65.5)

148(60.9)

25(37.3)

2257(64.6)

 > 5

1099(34.5)

95(39.1)

42(62.7)

1236(35.4)

Tumor Location, n(%)

< 0.001

 Colon

1890(59.1)

182(74.3)

40(59.7)

2112(60.2)

 Rectum

1306(40.9)

63(25.7)

27(40.3)

1396(39.8)

T, n(%)

< 0.001

 T3

2912(91.1)

218(89.0)

41(61.2)

3171(90.4)

 T4

284(8.9)

27(11.0)

26(38.8)

337(9.6)

Histology,n(%)

0.001

 Adenocarinoma

2953(92.5)

243(99.2)

62(92.5)

3258(92.9)

 Other^a

241(7.5)

2(0.8)

5(7.5)

248(7.1)

Differentiation, n(%)

0.006

 Poor

366(11.5)

19(7.8)

12(17.9)

397(11.3)

 Median

2244(70.3)

197(80.4)

45(67.2)

2486(70.9)

 Well

584(18.3)

29(11.8)

10(14.9)

623(17.8)

MMR status, n(%)

< 0.001

 pMMR

2750(87.7)

240(99.2)

64(95.5)

3054(88.7)

 dMMR

384(12.3)

2(0.8)

3(4.5)

389(11.3)

Vascular Invasion, n(%)

< 0.001

 No

3041(95.3)

207(84.5)

54(80.6)

3302(94.2)

 Yes

151(4.7)

38(15.5)

13(19.4)

202(5.8)

Harvested Lymph Nodes, n(%)

0.261

 > 12

2781(87.3)

215(87.8)

54(80.6)

3050(87.2)

 ≤ 12

406(12.7)

30(12.2)

13(19.4)

449(12.8)